Healthcare / BiotechnologyNasdaqCM
$14.33
+0.18 (+1.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-28.8M · quality 65.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$31M
P/E
N/A
•EV/EBITDA
N/A
•ROE
343.1%
↑Gross Margin
N/A
•Debt/Equity
-0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-122.0%
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.5M · net income $-10.9M · FCF $-10.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.5M | $8.5M | — | — | — |
| Net Income | $-10.9M | $-10.9M | $-53.9M | $-172.6M | $-240.8M |
| EBITDA | $-10.6M | $-10.6M | $-53.1M | $-171.8M | $-239.9M |
| EPS | — | — | -52.80 | -231.99 | -2.99 |
| Operating Margin | -108.2% | -108.2% | — | — | — |
| Net Margin | -128.7% | -128.7% | — | — | — |
| Balance Sheet | |||||
| Debt/Equity | -0.20 | -0.20 | 0.20 | 0.11 | -0.00 |
| Current Ratio | 0.96 | 0.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-10.4M | $-10.4M | $-28.8M | $-43.2M | $-43.2M |
| Returns | |||||
| ROE | 343.1% | 343.1% | -1107.3% | -418.6% | 53.7% |
| Valuation | |||||
| P/B | — | — | 2.24 | 1.64 | — |
| Growth & Yield | |||||
| EPS Growth | — | — | 77.2% | -7650.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+134.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-52.80 → n/d
Residual
+134.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.